Biotech Values

[mouton29]

The phase 2 trial also didn't show dose response, see page 19 of https://investors.revance.com/static-files/fa582118-0191-44ae-b904-bb3d91e0fc1c

Look at the results in week 12, the higher dose (purple line) shows smaller reduction from baseline.

I would have thought page 17 of the current phase 3 results, https://investors.revance.com/static-files/6e3e48cd-84a0-4bf4-8319-4874c1aba9db, is important, lower dose implies significantly smaller rate of dsyphagia, 1.6% compared to 3.9% at the higher dose a small fraction of the rate (13 - 19%) for competitor products.